| Literature DB >> 22440873 |
Jose A Carrillo1, Claudia A Munoz.
Abstract
Irinotecan, cisplatin, and nitrosoureas have a long history of use in brain tumors, with demonstrated efficacy in the adjuvant treatment of malignant gliomas. In the era of temozolomide with concurrent radiotherapy given as the standard of care, their use has shifted to treatment at progression or recurrence. Now with the widespread use of bevacizumab in the recurrent setting, irinotecan and other chemotherapies are seeing increased use in combination with bevacizumab and alone in the recurrent setting. The activity of these chemotherapeutic agents in brain tumors will likely ensure a place in the armamentarium of neuro-oncologists for many years. Published by Elsevier Inc.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22440873 DOI: 10.1016/j.nec.2012.01.005
Source DB: PubMed Journal: Neurosurg Clin N Am ISSN: 1042-3680 Impact factor: 2.509